1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

FDA Examination Of Homeopathic Regulation Looks Beyond Safety History

 
• By Malcolm Spicer

CDER Director Janet Woodcock says the current regulatory framework limits FDA’s direct regulation of homeopathics to post-market surveillance. During a two-day public hearing, agency officials question stakeholders about trials, labeling and how well consumers understand their products.

FDA officials agree with the homeopathic industry on its products’ strong safety record, but the agency might not be convinced that the drug category’s history is enough to justify continuing its current policy that defers regulation largely to the industry.

At the opening of a two-day public hearing on April 20 for comment on FDA’s homeopathic product oversight, Center for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

US FDA Could Miss User Fee Spending Triggers With House FY 2026 Funding

 
• By Sarah Karlin-Smith and Derrick Gingery

FDA employees are concerned that while the budget authority total proposed for fiscal year 2026 meets the user fee appropriations' triggers, the FDA could have trouble meeting allocation triggers without cuts to non-review work.

PCMA, CVS, Cigna File Lawsuits Over ‘Dangerous’ Arkansas PBM Law

 
• By Tim Casey

The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.